Zambia Pharmaceuticals and Healthcare Report Q1 2013


January 16, 2013
41 Pages - SKU: BMI4944038
License type:
Countries covered: Zambia

BMI View: The majority of investment in Zambia's healthcare market stems from international aidagencies - so the news that the government has increased its allocation for healthcare spending in the2013 budget will be well received by both NGOs and international investors as a sign that Zambia istaking its commitment to healthcare seriously. The country suffers from a burden of both communicableand non-communicable diseases, with a high incidence of HIV and AIDs, malaria, and problems such ascholera emerging in Q412, but it is making progress. The government claims it has already met itsmillennium development goals for turbercolosis, and is on target to meet other healthcare goals. Risksremain, such as the presence of counterfeit and substandard drugs, and the reliance on copper exportmeans Zambia's economy has a narrow base.

Headline Expenditure Projections

Pharmaceuticals: ZMK951bn (US$196mn) in 2011 to ZMK1,095bn (US$207mn) in 2012;

+15.1% in local currency terms and +5.7% in US dollar terms. Forecast lowered slightly from Q412.

Healthcare: ZMK5,347bn (US$1.10bn) in 2011 to ZMK6,290bn (US$1.19bn) in 2012; +17.6%in local currency terms and +8.0% in US dollar terms. Forecast lowered slightly from Q412.Risk/Reward Rating: In Q113, Zambia remained steady at 21st best market in the MEA region in BMI'sproprietary Risk/Reward Ratings (RRR) matrix with a score of 39.6.

Key Trends & Developments

Zambia's government claimed in October 2012 that it is on target to meet its MillenniumDevelopment Goals and has raised healthcare funding by 46% in its current budget. The year2013 will see the government spend ZMK3.46trn on healthcare, or 11% of total spending.

A refurbished eye clinic and centre of excellence, part funded by NGO Operation EyesightInternational, was opened in Lusaka in October 2012. Phase I of the project cost ZMK2.8bn, andwas constructed by India's Nava Bhata Ventures; Phase II will cost ZMK15.5bn.

The Global Fund signed an agreement with the Churches Health Association of Zambia inOctober 2012 to provide US$102mn to support the reduction of HIV and AIDs.

BMI Economic View: Zambia's minister of finance presented the 2013 budget seeking to stimulategrowth in sectors with relatively strong potential for generating employment.,This included a big increasein healthcare spending, from ZMK2.58trn to ZMK3.64trn. BMI believes that the economy has a strongoutlook, and that the business environment will remain stable.

BMI Political View: In the announcement of 2013's budget, the minister of finance revealed that thegovernment will try to promote transparency by ruling that any revenue collected by government bodiesmust be deposited in the treasury. Such moves will go some way to reassuring potential investors that thegovernment is serious about dealing with corruption.


BMI Industry View
Pharmaceutical Risk/Reward Ratings
Table: MEA Pharmaceuticals And Healthcare Risk/Reward Ratings, Q113
Rewards
Risks
Market Summary
Government Healthcare Reform
Regulatory Regime
Pharmacovigilance (PV)
Industry Forecast Scenario
Pharmaceutical Market Forecast
Table: Pharmaceutical Sales Indicators 2008-2016
Healthcare Market Forecast
Table: Healthcare Expenditure Indicators, 2008-2016
Table: Healthcare Governmental Indicators, 2008-2016
Table: Healthcare Private Indicators, 2008-2016
Key Growth Factors - Macroeconomic
Demographic Outlook
Table: Zambia's Population By Age Group, 1990-2020 ('000)
Table: Zambia's Population By Age Group, 1990-2020 (% of total)
Table: Zambia's Key Population Ratios, 1990-2020
Table: Zambia's Rural And Urban Population, 1990-2020
Glossary
BMI Methodology
How We Generate Our Pharmaceutical Industry Forecasts
Risk/Reward Ratings Methodology
Ratings Overview
Table: Pharmaceutical Business Environment Indicators
Weighting
Table: Weighting Of Components
Sources

More Manufacturing, Packaging & Detailing reports by Business Monitor International

Ukraine Pharmaceuticals and Healthcare Report Q1 2013 by Business Monitor International
BMI View: Foreign and domestic drugmakers in Ukraine will see their operating margins squeezedfrom 2013 as the Ministry of Health introduces more severe limits on ...
Sudan and South Sudan Pharmaceuticals and Healthcare Report Q1 2013 by Business Monitor International
BMI View: Sudan and South Sudan's will continue to be of least interest to foreign pharmaceutical firmsin the Middle East and North Africa region as ...
Portugal Pharmaceuticals and Healthcare Report Q1 2013 by Business Monitor International
BMI View: Portugal's pharmaceutical and healthcare sector has been transformed since the interventionof the EU, IMF and ECB as part of the country's EUR78bn economic ...
Poland Pharmaceuticals and Healthcare Report Q1 2013 by Business Monitor International
BMI View: The Polish pharmaceutical market contracted severely in 2012, owing to harsh pricingmeasures and strict margins imposed on wholesalers, pharmaceutical makers and retailers. Moreover,over ...
See all reports like this >>

More Zambia Manufacturing, Packaging & Detailing reports

Zambia Pharmaceuticals and Healthcare Report Q4 2012 by Business Monitor International
BMI View: Zambia’s healthcare industry has been boosted this quarter with the news of revivedinvestment via international aid agencies and donations. The Swedish government decided ...
Zambia Pharmaceuticals and Healthcare Report Q3 2012 by Business Monitor International
BMI View: The fundamentals of Zambia’s healthcare industry growth story remain strong with macroeconomic growth, returning international donations and government spending on healthcare forecast to ...
Zambia Pharmaceuticals and Healthcare Report Q2 2012 by Business Monitor International
BMI View: We believe Zambia is rapidly becoming one of the most promising markets in Sub-Saharan Africa. An increased focus on healthcare and preventing corruption ...
See all reports like this >>

More Zambia reports

D&B Country RiskLine Report: Zambia by Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...
D&B Country Report: Zambia by Dun & Bradstreet Inc.
D&B Country Report. Comprehensive information for evaluating risks and opportunities when trading or investing in this country. Providing critical information and analysis on ...
Country Report Zambia January 2011 by Economist Intelligence Unit
Country Reports analyse political and economic trends in featured countries. They show you exactly how national, regional and global events will affect your business in ...
See all reports like this >>